The role of multiple sclerosis therapies on the dynamic of human gut microbiota
Gut microbiota, the total microorganisms in our gastrointestinal tract, might have an implication in multiple sclerosis (MS), a demyelinating neurological disease. Our study included 50 MS patients and 21 healthy controls (HC). Twenty patients received a disease modifying therapy (DMT), interferon beta1a or teriflunomide, 19 DMT combined with homeopathy and 11 patients accepted only homeopathy. We collected in total 142 gut samples, two for each individual: at the study enrolment and eight weeks after treatment. (Source: Journal of Neuroimmunology)
Source: Journal of Neuroimmunology - April 7, 2023 Category: Allergy & Immunology Authors: Vitalie Vacaras, Dafin F. Muresanu, Anca-Dana Buzoianu, Cristina Nistor, Stefan Cristian Vesa, Andreea Cristina Paraschiv, Daniela Botos-Vacaras, Cristiana Vacaras, George Vithoulkas Source Type: research
Remdesivir Use Improves Mortality in COVID-19 in Non-ventilated Hospitalized Patients
Dr. Gibson
Clinical question: Does remdesivir have a mortality benefit in patients with COVID-19?
Background: The Solidarity trial previously reported preliminary mortality analyses for remdesivir, lopinavir, hydroxychloroquine, and interferon beta-1a use in COVID-19 inpatients. The latter three drugs were discontinued due to futility, but randomization to remdesivir continued. This review presents the final results of the Solidarity trial and all other relevant trials of remdesivir at the time of publication.
Study design: Randomized control trial and meta-analysis
Setting: Inpatients with COVID-19 infection from 454 hos...
Source: The Hospitalist - April 3, 2023 Category: Hospital Management Authors: Ronda Whitaker Tags: COVID-19 In the Literature Source Type: research
Eight-and-a-half syndrome as the first presentation of multiple sclerosis in an Asian male: a case report
ConclusionThis case illustrates eight-and-a-half syndrome as the first presentation of a diffuse central nervous system pathology. A wide range of differential diagnoses needs to be considered in such a presentation as based on the patient ’s demographics and risk factors. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - March 6, 2023 Category: General Medicine Source Type: research
GSE224351 Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-beta-1a Compared to Non-PEGylated IFN-beta-1a
Contributors : Kristi Nguyen ; Maya Olcer ; Quentin Howlett-Prieto ; Xuan Feng ; Anthony T RederSeries Type : Expression profiling by arrayOrganism : Homo sapiensTranscriptome analysis of RNA samples from human PBMCs of IFN-beta treated multiple sclerosis patients.Interferon (IFN)-b-1a (Avonex) and longer half-life, polyethylene glycol-conjugated IFN-b-1a (PEG-IFN-b-1a, Plegridy), may generate different molecular responses. At 6 h, non-PEGylated IFN-b-1a injection upregulated expression of 136 genes and PEG-IFN-b-1a upregulated 85. At 24 h, induction was maximal; IFN-b-1a upregulated476 genes and PEG-IFN-b-1a now upr...
Source: GEO: Gene Expression Omnibus - March 1, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
Discussion
The almost complete reduction of ARR and MRI activity already evident in the lowest quartile, and across all ocrelizumab-exposure groups, suggests a ceiling effect. A consistent trend of higher ocrelizumab exposure leading to greater reduction in risk of CDP was observed, particularly in the relapsing MS trials, and was not associated with a higher rate of adverse events. Higher ocrelizumab exposure may provide improved control of disability progression by reducing disease activity below that detectable by ARR and MRI, and/or by attenuating other B-cell–related pathologies responsible for tissue damage.
C...
Source: Neurology Neuroimmunology and Neuroinflammation - February 15, 2023 Category: Neurology Authors: Hauser, S. L., Bar-Or, A., Weber, M. S., Kletzl, H., Günther, A., Manfrini, M., Model, F., Mercier, F., Petry, C., Wing, Q., Koendgen, H., Smith, T., Kappos, L. Tags: Research Article Source Type: research
Recurrent encephalopathy associated with pegylated beta-interferon treatment
A 62-year-old woman with a history of multiple sclerosis (MS) presented with recurrent episodes of confusion, dysarthria and gait difficulties. These episodes occurred about 3 days after administration of pegylated interferon-beta-1a (Plegridy®) and resolved spontaneously in around 4 days. The brain MRI scan, laboratory findings and cerebrospinal fluid analysis during these episodes were negative for other causes of encephalopathy. She discontinued treatment with in terferon and was started on teriflunomide, experiencing no recurrence of symptoms. (Source: Journal of Neuroimmunology)
Source: Journal of Neuroimmunology - January 30, 2023 Category: Allergy & Immunology Authors: Francisca Ferreira, Daniel Ferreira, Joana Guimar ães, Ricardo Soares-dos-Reis Tags: Short Communication Source Type: research
Fingolimod significantly reduces MRI activity in paediatric-onset multiple sclerosis (MS)
Conclusion: Fingolimod significantly reduces MRI findings consistent with active disease and rate of relapses in paediatric MS. Commentary Paediatric MS accounts for 3%–5% of all cases and... (Source: Archives of Disease in Childhood - Education and Practice)
Source: Archives of Disease in Childhood - Education and Practice - January 19, 2023 Category: Pediatrics Authors: Chapman, L. Tags: Key publications in paediatrics: Picket Source Type: research
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease
AbstractMultiple sclerosis (MS) is a chronic autoimmune demyelinating and neurodegenerative disease of the central nervous system with a wide variety of clinical phenotypes. In spite of the phenotypic classification of MS patients, current data provide evidence that diffuse neuroinflammation and neurodegeneration coexist in all MS forms, the latter gaining increasing clinical relevance in progressive phases. Given that the transition phase of relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS) is not well defined, and widely accepted criteria for SPMS are lacking, randomised controlled trials (RCTs) specifical...
Source: CNS Drugs - January 4, 2023 Category: Neurology Source Type: research
Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development - (III) A Randomized Trial with Interferon Beta-1a Products
This study illustrates potential methodologies for evaluating PD biomarkers and an approach to address information gaps when limited information is publicly available for one or more PD biomarkers.PMID:36324229 | DOI:10.1002/cpt.2784 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - November 3, 2022 Category: Drugs & Pharmacology Authors: Jeffry Florian Victoria Gershuny Qin Sun Sarah J Schrieber Murali K Matta Anthony Hazel Morasa Sheikhy James L Weaver Paula Hyland Cheng-Hui Hsiao Giri Vegesna Ryan DePalma Aanchal Shah Kristin Prentice Carlos Sanabria Yow-Ming Wang David G Strauss Source Type: research
Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development - (III) A Randomized Trial with Interferon Beta-1a Products
This study illustrates potential methodologies for evaluating PD biomarkers and an approach to address information gaps when limited information is publicly available for one or more PD biomarkers.PMID:36324229 | DOI:10.1002/cpt.2784 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - November 3, 2022 Category: Drugs & Pharmacology Authors: Jeffry Florian Victoria Gershuny Qin Sun Sarah J Schrieber Murali K Matta Anthony Hazel Morasa Sheikhy James L Weaver Paula Hyland Cheng-Hui Hsiao Giri Vegesna Ryan DePalma Aanchal Shah Kristin Prentice Carlos Sanabria Yow-Ming Wang David G Strauss Source Type: research
Medications and the risk of perforated appendicitis: an adverse event report system (FAERS) database analysis
CONCLUSION: Findings from the FAERS database highlight the risk of appendiceal perforation in the context of different classes of drugs. Larger pharmacovigilance studies are needed to confirm these observations as well as overcome inherent reporting biases.PMID:36322707 | DOI:10.1080/17474124.2022.2143346 (Source: Expert Review of Gastroenterology and Hepatology)
Source: Expert Review of Gastroenterology and Hepatology - November 2, 2022 Category: Gastroenterology Authors: Daryl Ramai Daniel Mozell Antonio Facciorusso Anjali Kewalramani Saurabh Chandan Banreet Dhindsa Amaninder Dhaliwal Shahab Khan Douglas G Adler Source Type: research
